



BIOHEART

Media Contact: Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 772.285.8511
cmatton@bioheartinc.com

For Immediate Release

**Miami Dade College Names Bioheart CEO,
Mike Tomas, to Board of Advisors for New Idea Center**

Sunrise, FL – October 30, 2014 – Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced that Mike Tomás, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students. The Idea Center will include a venture incubator, called CREATE, with programming and resources to help nurture and accelerate the entrepreneurial ideas and ventures of students.

"Miami Dade College has long been recognized as being on the cutting edge of all things that will benefit their students and the community," said Tomas, President and CEO of Bioheart. "Miami is undergoing a huge transformation with an enormous focus on biotech, tech and entrepreneurship. As the CEO of Bioheart, I am excited that our company is right in the middle of it all."

The Idea Center at Miami Dade College was made possible with a \$2.18 million investment from the John S. and James L. Knight Foundation. Miami Dade College President Dr. Eduardo J. Padron announced the plan and the board this week.

"Entrepreneurship should be viewed as a skill to be taught, learned and used in the community. This mindset helps encourage the starting of new small businesses, which is the bedrock of the local economy," said President Padron.

Miami Dade College is the largest and most diverse college in the nation. With seven campuses, two centers and more than 165,000 students from across the world, the College offers over 300 programs of study and several degree options, including vocational associate and baccalaureate degrees.

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014.